The albuterol inhaler market in the United States will soon
change from low-value to significant. The only MDIs sold will be branded HFA
formulations; CFC propellants will be eliminated. Because the new HFA
formulations are not bioequivalent, companies will compete for market
leadership by convincing physicians and patients of their product’s superiority and by making strategic pricing
Questions Answered in This Report:
The imminent discontinuation of many generic formulations of
albuterol in the United States will be the most significant change in the
respiratory disease market in some time. Will today’s sales leaders weather
the change and continue to enjoy market dominance? How will the change affect
generics manufacturers? What marketing strategies will be key elements in
development of the market between 2006 and 2011? What are the market leaders
As production of albuterol CFC ends, patients will have to
switch from familiar generics to more-expensive, branded HFA formulations that
are not interchangeable despite having the same active ingredient. How can
companies differentiate their products to win patient and physician allegiance?
How will higher costs affect patients and reimbursement providers? How will
By the beginning of 2009, the U.S. market for inhaled
albuterol MDIs will comprise branded products exclusively. Which products
will drive the market at least until 2011? Which company is likely to
own the biggest market share in 2011? Which companies will lose market share?
Are new companies with new formulations likely to impact the market by 2011?
Respiratory disease market: asthma and chronic
obstructive pulmonary disease prevalence and treatment; albuterol agents and
Montreal Protocol: ban on CFC propellants; impact on
the albuterol market and on brand and generic manufacturers, consumers, and
From CFC to HFA: supply and demand challenges;
manufacturer compliance; non-bioequivalence of HFAs; reimbursement issues.
Market outlook: continuing demand for albuterol
products; DPI formulations; pricing and product differentiation; U.S. market
forecast; winners and losers.